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We report the isolation of the 50 flanking region of GRAF (GTPase regulator associated with the focal adhesion kinase), previously
described as a putative tumour suppressor gene of acute myelogenous leukaemia and myelodysplastic syndrome, and demonstrate its
promoter activity in reporter gene assays. Two putative protein-binding sites are identified of which one was sensitive to CpG
methylation. The suppressed GRAF expression could be restored in leukaemia cell lines by treatment with a demethylating agent and
an inhibitor of histone deacetylases. In contrast to normal tissues, which tested negative for GRAF promoter methylation, 11 of 29
(38%) bone marrow samples from patients with acute myeloid leukaemia or myelodysplastic syndrome were positive.
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The GRAF (GTPase regulator associated with the focal adhesion
kinase) gene at chromosome 5q31 has been identified as a
translocation partner of MLL (also known as ALL-1, HRX or
HTRX) in a case of juvenile myelomonocytic leukaemia (Borkhardt
et al, 2000). GRAF has some unusual features with regard to its
tumour suppressor properties. It is localised in the cytoplasm
and negatively regulates the small GTP-binding protein RhoA
(Hildebrand et al, 1996), which in turn is well known for its
growth-promoting effect in RAS-mediated malignant transformation
(Qiu et al, 1995).
GRAF function is affected by mutations and deletions of the
gene in patients with acute myeloid leukaemia (AML) or
myelodysplastic syndrome (MDS) (Borkhardt et al, 2000) and we
hypothesised that GRAF function could also be affected by
downregulation induced by methylation of its promoting regions
as shown for established tumour suppressor genes (e.g. hMLH1,
HIC1, E-cad, VHL, CDKN2, RB, BRCA1) (Herman et al, 1994, 1998;
Gonzalez-Zulueta et al, 1995; Yoshiura et al, 1995; Dobrovic
and Simpfendorfer, 1997; Graff et al, 1997; Jarrard et al, 1997;
Ohtani-Fujita et al, 1997; Melki et al, 1999). Thus, we isolated the
50 regulatory region of GRAF by genome walking, characterised it
by reporter gene assays and looked therein for methylation-
sensitive protein-binding sites. We tested partially and fully
methylated alleles of the GRAF promoter by luciferase reporter
gene assays. The influence of epigenetic modifications on the
GRAF expression was further studied by quantitative PCR in
leukaemia and lymphoma cell lines of different origin after
treatment with the demethylating agent 5-aza-20-deoxycytidine
(5-azadC) or the histone deacetylase inhibitor trichostatin A (TSA).
Finally, we screened a series of bone marrow samples from
patients with AML or MDS by methylation-sensitive PCR (MS-
PCR).
MATERIALS AND METHODS
50 rapid amplification of cloned ends
PCR products generated by a nested 50 rapid amplification of
cloned ends (RACE) with gene-specific primers (Table 1) against
adaptor primers on an adaptor-ligated cDNA library from the cell
line K562 (Clontech, Palo Alto, CA, USA) according to the
manufacturer’s specifications were cloned into pBluescriptIISKþ
(Stratagene, Heidelberg, Germany). The five longest of 25 clones
from three independent PCR experiments were sequenced (ABI/
Perkin-Elmer, Langen, Germany).
Genome walking and construction of reporter plasmids
The genome walking was performed as a nested hot-start long-
range PCR (conditions available upon request) with the five
human templates from the Genome Walker kit #K1803-1
(Clontech, Palo Alto, CA, USA). PCR products were cloned and
sequenced. The sequence of the 50 region thus obtained was used
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sto generate PCR fragments, which were cloned into the pGL3-Basic
vector using the restriction sites HindIII and BglII. Plasmids were
sequenced before proceeding to the dual luciferase assay.
Cell cultivation and transfection
The human chronic myeloid leukaemia cell line K562 was cultured
in RPMI 1640 medium (Gibco BRL, Karlsruhe, Germany)
supplemented with 10% fetal calf serum, 260mgl
 1 L-glutamine,
50000Ul
 1 penicillin and 50mgl
 1 streptomycin. The cells were
split 1:10 once a week and split 1:10 4 days before each
transfection experiment.
RAW264 is a murine macrophage cell line and was cultured in
DMEM (Gibco BRL, Karlsruhe, Germany) supplemented with 10%
fetal calf serum, 260mgl
 1 L-glutamine, 50000Ul
 1 penicillin and
50mgl
 1 streptomycin.
Daudi was established from a Burkitt’s lymphoma. Jurkat is a
human T-cell leukaemia cell line. Kasumi-1 was derived from an
AML (M2) harbouring a t(8;21). Mutz-1 was established from a
patient with MDS and Fanconi anaemia. These cell lines were
cultivated under the same conditions as K562.
Trichostatin A was dissolved in ethanol and added to the
cell medium (RPMI or DMEM) to an end concentration of
100–300ngml
 1.
Reporter gene assays
K562 cells were transiently transfected with DMRIE-C (Gibco BRL,
Karlsruhe, Germany). Reporter gene assays were performed using
the dual luciferase reporter assay system (Promega, Mannheim,
Germany) as described by the manufacturer. In short, the cells
were co-transfected with two different plasmids, each coding for a
luciferase: the Renilla luciferase coded for by the pRL-TK plasmid
and the firefly luciferase coded for by the pGL3 plasmid. The two
enzymes each have high specificity to their own substrates with
minimal low cross-activities. For each transfection experiment,
the activity of each enzyme was measured sequentially in a lumino-
meter (AutoLumat LB953, Berthold, Bad Wildbad, Germany).
The pRL-TK plasmid served as an internal control for each
transfection, correcting for varying transfection efficiency. The
relative activity of the pGL3 plasmid containing various fragments
of the GRAF promoter was normalised against the activity of the
SV40 promoter (¼100%; Figure 1B) or the activity of the empty
pGL3 plasmid (¼1; Figure 3D and E).
In vitro modifications of the GRAF promoter
A4 0mg portion of the pGL3-Basic plasmid containing the –986 to
 1 fragment of the GRAF promoter was digested with BglII and
HindIII and separated by electrophoresis. The promoter fragment
was excised from the agarose gel, purified and resolved. The
fragment was methylated by M.SssI methylase (New England
Biolabs, Schwalbach, Germany) with 10U enzymemg
 1 DNA in the
presence of 320mM S-adenosylmethionine (New England Biolabs,
Schwalbach, Germany) for 60min at 371C. The methylation was
controlled by digestion with the methylation-sensitive restriction
enzyme BstUI. The methylated DNA fragment and an unmethy-
lated control fragment were each ligated into the pGL3-Basic
vector prepared by BglII/HindIII digestion. After ligation had been
confirmed by agarose gel analysis, the ligation mixture was
purified using the Plasmid Mini Kit (Qiagen, Hilden, Germany). A
1mg portion was subsequently used for the dual luciferase assay
(Figure 1B) as described above.
For the DNase I protection assays, the methyltransferases M.SssI
and M.FnuDII (New England Biolabs, Schwalbach, Germany) were
used to methylate the promoter fragments according to the
manufacturer’s protocol.
The plasmid constructs with deleted putative DNA–protein-
binding sites (Figure 3D) were generated by site-directed PCR
mutagenesis according to Weiner et al (1994).
Preparation of nuclear extracts and DNase I protection
assays
Nuclear protein extracts from RAW264 and K562 cells were
prepared as described previously (Dignam et al, 1983; Shapiro
et al, 1988). Briefly, after nearly reaching confluence, cells from 100
cell culture dishes (15cm) were harvested and resuspended in
hypotonic buffer (for buffer compositions, see Supplementary
Table C). Nuclei were released and sucrose restore buffer was
added. After pelleting and lysing the nuclei by adding nuclear
resuspension buffer, debris was removed by centrifugation and
nuclear proteins were precipitated. Finally, the nuclear extract was
dialysed against buffer D, aliquoted and stored at  801C until use.
The unmethylated or methylated (by M.FnuDII or M.SssI)
promoter fragment ( 576 to  75) was released from 10mg plasmid
DNA by a BglII and HindIII digest and radioactively end-labelled
with 15U Klenow fragment in the presence of 50mCi [a-
32P]dGTP
and non-radioactive dATP, dCTP and dTTP. The promoter
fragment was isolated by agarose gel electrophoresis and
Table 1 Primer list
Assay Orientation Nucleotide sequence (50-30)
Rapid amplification of cloned ends
1 Adaptor primer 1, forward CCATCCTAATACGACTCACTATAGGGC
1 Gene-specific primer 1, reverse AATTTGTTGGTCTTGTCCAGCTCTGCTTCGTGCG
2 Adaptor primer 2, forward ACTCACTATAGGGCTCGAGCGGC
2 Gene-specific primer 2, reverse GCACCGCGGCTTGAGCGTCTCTCGGAAGTGCGGACTATCGAG
Methylation-sensitive PCR
1 Forward GATTAAGATCGCGGAAGGGTCG
1 Reverse AACTCTCGACAACCTCGAACGC
2 Forward CGTTTTCGGGCGGTTTGAGGGTC
2 Reverse CCTCTCACAACAACCTCGACCG
Real-time PCR
1 GRAF-F CAGAACATTGTCATTGAGATCCTAATAGA
1 GRAF-R GGGCATTGGTGAGAGGCATA
1 GRAF probe AACCACGAAAAGATATTTAACACCGTGCCCGA
1 ABL-F CAACACTGCTTCTGATGGCAA
1 ABL-R CGGCCACCGTTGAATGAT
1 ABL probe CAACACCCTGGCCGAGTTGGTTCAT
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s30000c.p.m. of DNA were incubated in binding buffer (Nickel
et al, 1995) supplemented with 1mg of dIdC and various amounts
of nuclear extracts as indicated in the figures. Subsequently, a
DNase I digest was performed in a total volume of 60ml for 10min
on ice or at room temperature. The chosen incubation conditions
only allowed an incomplete digestion, leaving a specific population
of partially digested promoter fragments. The reaction was
terminated by adding 2 volumes of stop buffer and 30mgo f
proteinase K and incubation at 551C for 30min. The promoter
fragments were extracted and subjected to electrophoresis on a 6%
polyacrylamide, 8 M urea gel, thereby separating the partially
digested DNA fragments according to size. A GþA ladder served
as a marker of size. Finally, the dried gel was autoradiographed on
an X-ray film.
Nuclear proteins binding to the DNA could decrease the
accessibility of the DNA for DNase I, thus leading to regions on
the DNA protected from digestion. The binding could also induce
conformational changes of the DNA, increasing the accessibility of
the DNA for nucleases and leading to hypersensitive sites.
Accordingly, DNase I protection/hypersensitivity is assumed to
represent protein binding to the promoter fragment and is
recognised as a change in the migration pattern from the lane
without nuclear extract to the lanes with nuclear extract. In an
attempt to quantify the effect, we used increasing amounts of
Farthest 5′ end of cDNA
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Figure 1 Overview (A) and deletion analyses (B) of the GRAF promoter. (A) The GRAF promoter is a GC-rich area with a dense concentration of CpG
dinucleotides and a CpG island extending from  981 in the promoter to þ350 in the downstream intron (numbering of nucleotides relative to A (¼þ1)
in the START-ATG codon). Segment  986 to  1 was examined with reporter gene assays. (B) Left panel: The promoter segments (numbering relative to
A(¼þ1) in the START-ATG codon). Right panel: Relative firefly luciferase activity normalised against the promoting activity of SV40 (¼100%). K562 cells
were transiently transfected with a pGL3 plasmid containing different segments of the GRAF promoter. Inversion (arrow) or methylation of the promoter
completely abolishes any promoting activity. The data represent the mean7s.d. of three independent experiments.
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sDNase I or nuclear extract. If methylation of the promoter
fragment is able to abolish this change of migration from the lane
without nuclear extract to the lanes with nuclear extract, we
interpret this as abolishment of protein binding.
Quantification of GRAF mRNA by real-time PCR
For the quantification of the GRAF mRNA, a TaqMant PCR assay
in combination with an ABI PRISMt 7700 Sequence Detector
(Applied Biosystems, Foster City, CA, USA) was used. After
isolation of total RNA with Trizolt reagent (Invitrogen, Karlsruhe,
Germany), reverse transcription of 1mg of RNA was performed
using Superscript II reverse transcriptase (Invitrogen, Karlsruhe,
Germany) and oligo-dT primers (Sigma, Schnelldorf, Germany)
according to the manufacturer’s recommendations. A 1ml portion
of this cDNA served as template in a 25ml two-step qPCR reaction
(conditions are available upon request; for primer and probe
sequences, see Table 1, PCR product: 81bp). Each PCR was
performed in triplicate and the number of GRAF mRNA molecules
was determined according to a standard curve generated by a
plasmid dilution series and normalised to the number of ABL
mRNA molecules in a corresponding preparation.
Patients’ samples
Bone marrow samples from 29 paediatric patients suffering from
AML or MDS were collected in the framework of the Berlin–
Frankfurt–Muenster (BFM) study group. The selection of cases
was biased with regard to availability of frozen tumour material as
a prerequisite for the analysis. All samples were sent by mail to the
Oncogenetic Laboratory of the Children’s University Hospital
in Giessen, Germany. We were not aware of any differences in
tissue processing among the 29 samples studied. The mononuclear
cells were separated by Ficoll
s density gradient centrifugation
according to the manufacturer’s instructions (Serva, Heidelberg,
Germany). The cells were resuspended in 250ml PBS, shock frozen
in liquid nitrogen and stored at  801C until analyses.
Methylation-sensitive PCR
The MS-PCR was performed basically as described by Herman
et al (1996). In brief, 1mg genomic DNA in a volume of 70ml was
denatured by NaOH treatment (final concentration 0.33 M) for
15min at 371C, 3min at 951C and 30min at 801C. Modification of
unmethylated cytosine residues was performed by adding 1ml of
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Figure 2 Footprint 1 site (Fp1). (A) Sequence of the footprint 1 site. The ciphers I, II and III correspond to the footprinting positions from the DNase I
protection assay. The DNase I-protected position is shown in bold and DNase I-hypersensitive positions are underlined. The recognition sequence of
M.FnuDII is boxed. (B) DNase I protection assays. Methylation of the promoter fragment modifies binding of nuclear extract proteins to footprint 1 site.
Compared to the promoter fragments partially digested by DNase I alone (lane 1), addition of nuclear extracts (90mg) from K562 cells changed the
digestion pattern. While one signal (I) is reduced, the intensity of two other bands is increased (II and III). M.SssI methylates every cytosine residue in a CpG
dinucleotide, and this methylation abolishes binding of trans-acting factors (lanes 4–6 are essentially identical). M.FnuDII only methylates the lateral cytosin
residues in a CpG tetranucleotide and apparently this hemimethylation does not inhibit protective binding of trans-acting factors (lanes 7–9 are essentially
identical to lanes 1–3). The AþG ladder (lane 10) shows the reverse complementary sequence. Numbers refer to positions relative to A in the START-
ATG (¼þ1); the M.FnuDII recognition sequence is boxed. (C) DNase I protection assays: The binding of the trans-acting factors is not cell specific. DNase I
protection assay with increasing amounts (20, 50, 90 and 120mg) of nuclear extracts. Band I loses intensity as the amount of nuclear extracts is increased,
whereas bands II and III gain intensity. Thus, band I is protected by protein binding and bands II and III are hypersensitive to DNase digestion by protein
binding, regardless of the source of the nuclear extract.
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s3 M NaSO3 (Sigma, Schnelldorf, Germany) prewarmed at 551C and
incubation under mineral oil for 4h in the dark at 551C.
Subsequently, the modified DNA was purified using the Geneclean
Kit (Bio 101, Vista, CA, USA). DNA was resuspended in 20mlH 2O
and used immediately or stored at  201C.
PCR was performed as a nested hot-start PCR (conditions
available upon request) with the primers listed in Table 1.
In parallel, for each MS-PCR, appropriate PCR controls using
unmethylated (negative control) and in vitro-methylated genomic
DNA (positive control) isolated from a healthy volunteer were
performed.
The MS-PCR products (126bp) were visualised on a 2% agarose
gel and sequenced.
RESULTS
Isolation and characterisation of the 50 flanking region of
GRAF
Multiple 50 RACE-PCR products were sequenced and the 50 farthest
cDNA fragment began only 37bp upstream of the first ATG codon
(GenBank accession no. Y10388). Next, we isolated a sequence of
3080bp upstream of the presumed translation initiation codon by
genome walking (GenBank accession no. AF196313).
A CpG island/HTF (HpaII tiny fragment) according to the
definition of Gardiner-Garden and Frommer (1987) spanning the
first 981bp immediately upstream of the presumed translation
initiation codon, an exon and the first 350bp of the adjacent intron
was identified (Figure 1A). We did not find a TATA box or other
well-known transcription initiation signals.
Next, we performed reporter gene assays with a series of 50- and
30-deleted GRAF promoter constructs generated by inserting PCR
products into the pGL3-Basic vector just upstream of the firefly
luciferase gene. The intact 50 flanking region of GRAF is a powerful
promoter in K562 cells with about three times the activity of the
SV40 promoter (Figure 1B). Deletion experiments demonstrated
that the 50 end of the region examined is of minor importance for
the promoter activity. The smallest fragment with intact activity
proved to be the  576 to  365 fragment (data not shown). Further
50 deletions abolished the activity. The activity of the reversed
segment  981 to  1 proved to be approximately 1/50 of that of the
unreversed segment. Thus, the promoter activity of the 50 flanking
981bp is dependent upon direction. CpG methylation with the
M.SssI methylase diminished the activity of the  981 to  1
fragment to approximately 1/7 of the activity of the unmethylated
construct, which suggests that binding of trans-acting factors
might be dependent upon DNA demethylation. We therefore tried
to identify these sites using DNase I protection assays.
In vitro DNase I protection assays revealed a putative protein-
binding site from position  475 to  496 (Fp1; Figure 2), which
was apparent from the changes in the DNase I restriction pattern
on adding nuclear extract (Figure 2B, lane 1 vs lanes 2þ3). This
protein DNA interaction proved to be methylation sensitive, as
methylating the DNA by using M.SssI abolished the interaction
(Figure 2B, lane 4 vs lanes 5þ6). However, hemimethylating the
DNA with M.FnuDII failed to prevent protein loading to the DNA
(Figure 2B, lane 7 vs lanes 8þ9).
Next, we checked whether protein loading to the GRAF
promoter is cell type specific. However, we did not detect any
difference in the DNase I restriction pattern when performing
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Figure 3 Footprint 2 site (Fp2). (A) Sequence of the footprint 2 site (Fp2). The sequence marked with bold is protected from DNase I digestion by
binding of trans-acting factors. (B) DNase I protection assays: The segment  555 to  528 is protected from DNase I digestion (lanes 2 and 5: 40ng; lanes 3
and 6: 80ng DNase I) by binding of trans-acting factors from nuclear extract from K562 cells (90mg). This binding is insensitive to M.SssI methylation of the
DNA, as the DNA methylation does not alter the restriction pattern. The protected segment is marked by the black bar. The AþG ladder (lane 7) shows
the reverse complementary sequence. Numbers refer to positions relative to A in the START-ATG (¼þ1). (C) The interaction of proteins with the Fp2
region of the GRAF promoter is not cell specific. Nuclear extracts from both RAW264 and K562 cells (90mg) can protect unmethylated DNA from digestion
with increasing amounts of DNase I (40, 80 and 180mg). (D) Deletion of the footprint sites Fp1 and Fp2 reduces the promoter activity. Left panel: The
promoter segments (numbering relative to A (¼þ1) in the START-ATG codon). Right panel: Relative luciferase activity normalised against the promoting
activity of the empty pGL3 plasmid (¼1). The data represent the mean7s.d. of three independent experiments. (E) Promoting repression by the M.FnuDII
hemimethylation is partially reversible by incubation with the histone deacetylase inhibitor TSA, whereas CpG methylation with M.SssI causes a complete
block of the promoting activity, which cannot be restored by incubation with TSA. The reporter activities are shown as folds of increase of luciferase activity
compared to the empty pGL3 plasmid. The data represent the mean7s.d. of three independent experiments.
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sprotection assays in the presence of nuclear extracts prepared from
either K562 or RAW264 cells, a mouse macrophage cell line
(Figure 2C).
A second putative binding site, footprint site (Fp2), was
identified (Figure 3). For Fp2 however, protein binding was not
methylation sensitive (Figure 3B) and, as for Fp1, the protein
loading was not cell type specific (Figure 3C).
Confirmatory deletions of the two putative protein-binding sites
from the promoter reduced the promoting activities in dual
luciferase reporter assays (Figure 3D). Dual luciferase reporter
assays with unmethylated and M.FnuDII- or M.SssI-methylated
promoter constructs demonstrated methylation sensitivity of the
promoter. Thus, pGL3 constructs containing an unmethylated
GRAF promoter showed higher relative activity than M.FnuDII-
methylated constructs, which had a higher relative activity than the
completely methylated M.SssI constructs. The relative activity of
the M.FnuDII-methylated constructs could be partially restored by
incubating the cells with an inhibitor of histone deacetylase, TSA.
However, TSA could not restore the activity of the fragments
completely methylated by M.SssI (Figure 3E).
Influence of chromatin modifications on GRAF expression
To test the influence of a demethylating agent on the GRAF
expression in five leukaemia and lymphoma cell lines, they were
treated with 5-azadC during at least one replication cycle. 5-Aza-
20-deoxycytidine is a nucleotide analogue inhibiting DNA methyl-
transferase 1, which has to be incorporated into newly synthesised
DNA. An integration rate of 0.3% is sufficient to inhibit 95% of
methyltransferases (Creusot et al, 1982), as the enzymes become
covalently bound to 5-azadC. The subsequent demethylation of the
DNA leads to an activation of genes previously inactivated by
methylation (Juttermann et al, 1994). Quantitative PCR analyses of
5-azadC-treated cells vs untreated cells revealed an increase of
GRAF expression in Mutz-1 and K562 and a highly significant
increase in the AML cell line Kasumi-1 (Figure 4A). Morphologi-
cally, we did not notice any changes (data not shown).
To test the influence of the histone deacetylase inhibitor TSA,
five leukaemia and lymphoma cell lines were treated with 100–
300ng TSA per ml culture medium for 16h. Quantitative PCR
showed an enhanced GRAF expression in all cell lines examined,
but the TSA concentration necessary to achieve this effect varied.
In the myeloid cell line Mutz-1, 100ngml
 1 TSA had no effect,
whereas 200 and 300ngml
 1 TSA elevated the GRAF expression
level two- and three-fold vs the untreated controls. In Kasumi-1
and K562, 300ngml
 1 was necessary to double the GRAF
expression. In contrast, treating the Jurkat (derived from T-cell
leukaemia lymphoma) and Daudi (lymphoma) cell lines with
100ngml
 1 TSA elevated the GRAF expression four- and seven-
fold compared to the untreated controls (Figure 4B). The influence
GRAF expression + TSA B
A GRAF expression + 5-azadC
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Figure 4 GRAF expression levels in cell lines after treatment with 5-azadC and TSA. (A) Expression levels of GRAF analysed by quantitative RT–PCR
relative to a housekeeping gene (ABL) in cells treated with 5mM 5-azadC for 72h vs untreated controls. *Po0.05; **Po0.005 (t-test of untreated vs
treated). The data represent the mean7s.d. of three independent experiments. (B) Expression levels of GRAF by quantitative RT–PCR relative to a
housekeeping gene (ABL) in cells treated with 0–300ng TSA per ml culture medium for 16h. *Po0.05; **Po0.005 (t-test of untreated vs treated). The
data represent the mean7s.d. of three independent experiments.
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sof a combination of TSA and 5-azadC on GRAF expression levels
has not been tested.
CpG methylation of the GRAF promoter in patients with
AML/MDS
Methylation-sensitive PCR was used to reveal the presence of a
deactivating CpG methylation in the 50 flanking region. Bone
marrow and peripheral blood from 37 healthy donors and
bone marrow samples from 29 patients with AML or MDS were
analysed by MS-PCR and sequencing of the MS-PCR-positive
products. Among the healthy individuals, only one out of 37
showed a positive MS-PCR (2.7%). The sequence of this PCR
product revealed methylation of the cytosine residues at the
primer-binding sites but not within the PCR product. We
therefore interpret this as a technical error. In 11 out of 29 patient
samples (38%), a PCR product was generated, indicating
a methylated GRAF promoter (Figure 5A and Table 2). Six
PCR products were sequenced showing a complete methylation
of the cytosine residue in CpG dinucleotides (Figure 5B).
Unfortunately, lack of sufficient patient material prevented
us from testing the GRAF protein expression by immuno-
histochemical analysis or to correlate GRAF methylation status
with GRAF expression.
DISCUSSION
The GRAF gene located at chromosome 5q31 is a rare fusion
partner of MLL in cases of AML. So far, the fusion has been
reported in only three cases, all resulting in similar clinical features
(Borkhardt et al, 2000; Panagopoulos et al, 2004; Wilda et al, 2005).
In the present study, we identify and characterise the regulative
region of the GRAF gene. The GRAF promoter lacks a TATA or
CCAAT box, but the transcription initiation site is flanked by a
CpG island as described for other genes (Gardiner-Garden and
Frommer, 1987).
CpG islands are well-known targets of epigenetic modifications.
Methylation of cytosine residues is responsible for silencing of
transposable elements, for defence against viral sequences and for
the transcriptional repression of genes. The methylation status is
heritable through cell divisions and maintained by a number of
DNA methyltransferases (Egger et al, 2004).
To address the question whether GRAF expression might be
compromised by other mechanisms in patients without MLL-
GRAF fusion, we examined bone marrow samples from patients
with AML or MDS. In previous studies, three out of 13 samples
with loss of one 5q allele exhibited a disruption of the second
GRAF allele by insertions (Borkhardt et al, 2000). Therefore, if
GRAF has tumour-suppressing abilities, we assume that additional
mutations or epigenetic modifications contribute to the malignant
Controls AML/MDS patients
126 bp
–+
A
B
Position –475 –455 –435
Position –415 –395 –375 –355
GP cgtcctcggg cggcctgagg gtcgggcagg ggagggtgcg ctgattggcc cggcggggat…
UP cgtttttggg tggtttgagg gttgggtagg ggagggtgtg ttgattggtt tggtggggat…
MP cgttttcggg cggtttgagg gtcgggtagg ggagggtgcg ttgattggtt cggcggggat…
2 ccttttccgg ccgtttgagg gtcgggtagg ggagggtgcg ttgattggtt cggcggggat…
3 ccttttccgg ccgtttgagg gtcgggtagg ggagggtgcg ttgattggtt cggcggggat…
4 ccttttccgg ccgtttgagg gtcgggtagg ggagggtgcg ttgattggtt cggcggggat…
5 ccttttccgg ccgtttgagg gtcgggtagg ggagggtgcg ttgattggttc g g c g g g g a t …
6 ccttttccgg ccgtttgagg gtcgggtagg ggagggtgcg ttgattggttc g g c g g g g a t …
15 ccttttccgg ccgtttgagg gtcgggcagg ggagggtgcg ttgattggtt cggcggggat…
GP …taagtcatcg ctagcaggtt cgagcggccc agacaccggc ggggcggccg aggctgctgt gagagg
UP …taagttattg ttagtaggtt tgagtggttt agatattggt ggggtggttg aggttgttgt gagagg
MP …taagttatcg ttagtaggtt cgagcggttt agatatcggc ggggcggtcg aggttgttgt gagagg
2 …taagttatcg ttagtaggtt cgagcggttt agatatcggc ggggcggtcg aggttgttgt gagagg
3 …taagttatcg ttagtaggtt cgagcggttt agatatcggc ggggcggtcg aggttgttgt gagagg
4 …taagttatcg ttagtaggtt cgagcggttt agatatcggc ggggcggtcg aggttgttgt gagagg
5 …taagttatcg ttagtaggtt cgagcggttt agatatcggc ggggcggtcg aggttgttgt gagagg
6 …taagttattgt t a g caggtt cgagcggtct agatatcggc ggggcggtcg aggttgttgt gagagg
15 …taagttgtcg ttagtaggtt cgagcggttt agatatcggc ggggcggtcg aggttgttgt gagagg
Figure 5 Methylation-sensitive PCR of the GRAF promoter in patients’ samples. (A) Methylation-sensitive PCR. A 126bp fragment of the GRAF promoter
(segment  475 to  350) was amplified by applying MS-PCR. An artificially M.SssI-methylated promoter construct served as a positive control. (B)
Sequences of MS-PCR products. Alignment of six PCR products ( 475 to  350) generated from patient samples showing complete methylation of CpG
dinucleotides within the GRAF promoter. Numbering refers to patients in Table 2. GP¼germline promoter sequence; UP¼unmethylated promoter
sequence after MS-PCR; MP¼methylated promoter after MS-PCR. Bold cytosine and guanine residues indicate sequence variations and inverted thymidine
residues indicate a lack of methylation. Primer sequences are framed.
Characterisation of the GRAF gene promoter
SE Bojesen et al
329
British Journal of Cancer (2006) 94(2), 323–332 & 2006 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
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GRAF expression. The involvement of epigenetic modifications
such as promoter methylation is well known for a variety of
established tumour suppressor genes, the most prominent
examples being the retinoblastoma gene product and the cyclin-
dependent kinase inhibitor CDKN2A. For both genes, dense
hypermethylation of the promoter leads to a loss of gene
expression (Herman, 1999). Likewise, epigenetic events (hyper-
methylation) in the genes hMLH1, p16INK4A and GSTPI can also
lead indirectly to tumour progression by promoting genetic
instability in several tumour entities, such as breast, prostate,
gastric or colon cancer (Baylin and Herman, 2000; Herman and
Baylin, 2003). Along these lines we show a repression of activity
owing to methylation of the GRAF promoter. Two areas with
special importance for the activity of the promoter have been
identified and examined by DNase I protection assays (footprint
sites Fp1 and Fp2). These in vitro assays indicated the binding of
two factors to the GRAF promoter. Presumably, both factors are
not expressed in a cell-specific manner. The Fp1 region contains
three CpG dinucleotides of which an incomplete methylation by
M.FnuDII did not interfere with the binding of the protein factor.
Only complete methylation by M.SssI abolished the binding,
indicating an interference of the methylated 30 cytosine within the
methylase recognition site (CGCG) with the DNA binding of the
protein. Thus, the interaction of the protein with Fp1 is
methylation sensitive, as has been found for a variety of
transcription factors such as CREB, NF-kB, E2F or AP2 (Kovesdi
et al, 1987; Iguchi-Ariga and Schaffner, 1989; Comb and Goodman,
1990; Bednarik et al, 1991; Baylin and Herman, 2000; Herman and
Baylin, 2003).
A second factor interacts with footprint site 2 (Fp2) but without
exhibiting methylation sensitivity. Similar behaviour has been
demonstrated for the transcription factors CTF and YY1 (Ben
Hattar et al, 1989; Gaston and Fried, 1995). Nevertheless, it is
possible that modifications of the chromatin structure as a
consequence of the DNA methylation block the binding of a
protein factor in vivo although the factor is methylation insensitive
in vitro, as is known for NF-Y (Ammerpohl et al, 1997, 1998). As
our attempt to identify both binding factors by yeast one-hybrid
assays failed, these important transcriptional regulators have to be
identified in further studies.
Methylation of the GRAF promoter in patients with AML or
MDS was examined by MS-PCR, in which methylated and
unmethylated alleles are distinguished by conversion of all
unmethylated, but not of the methylated, cytosine to uracil
residues with bisulphite (Herman et al, 1996). In 38% of AML
and MDS patients, we detected methylation of the GRAF promoter.
Within a control group of 37 blood donors, only one incompletely
methylated GRAF promoter was detectable (3%), indicating a
highly increased rate of GRAF promoter methylation in haemato-
logic disorders of myeloid origin.
GRAF expression is also influenced by the histone acetylation
status. Acetylation and deacetylation of nucleosomal histones
are important cellular tools for the regulation of gene expression.
Hyperacetylated histones are associated with gene activity
whereas a lack of acetylation leads to the repression of gene
expression (Marks et al, 2003). These epigenetic modifications
are catalysed by two groups of enzymes, histone acetyl transferases
and histone deacetylases (HDACs). Inhibition of HDACs is
thought to augment gene transcription, as the histones cannot
be changed to their highly condensed, hypoacetylated form
(Kim et al, 2003). Application of TSA leads to an enhancement
of GRAF expression, especially in the non-myeloid cell lines
tested. The effect was dose dependent in the myeloid cell
lines, which required at least twice as much TSA as the non-
myeloid cell lines, indicating an additional layer of modification
regulating GRAF expression in these cells. Trichostatin A induces
significant changes in gene expression in only 2% of all genes
(Marks et al, 2001), so histone acetylation seems to play a specific
role in the regulation of GRAF gene expression. The different
developmental lines in haematological differentiation therefore
seem to become manifest in different GRAF chromatin patterns.
Histone deacetylase inhibitors are tested in clinical trials, as
they are known to induce growth arrest, differentiation and/or
apoptosis in cells of various tumour types (Marks et al, 2000,
2001).
It has been shown extensively by others that treatment
of leukaemia cell lines employed in our work (Daudi, Jurkat,
Kasumi-1, Mutz-1 and K562) with the HDAC inhibitor TSA or
the DNA methyltransferase 1 inhibitor 5-azadC has a profound
impact on the expression of several genes and decreases
proliferation and clonogenic survival and increases the level of
apoptotic markers (Blagosklonny et al, 2002; Zhu and Otterson,
2003; Karagiannis et al, 2004; Liu et al, 2004; Yokota et al, 2004;
Furukawa et al, 2005). Therefore, it is not surprising that the
expression level of GRAF seems to be influenced as well. Our
findings are consistent with the fact that treatment of cells with
5-azadC leads to an enhancement of GRAF expression only in
myeloid cells, especially in a cell line derived from an AML.
However, additional work is necessary to characterise the nature of
these interactions in more detail in myeloid leukaemia vs MDS.
Whether CpG methylation of the GRAF promoter and/or the GRAF
expression level could improve the initial diagnosis, stratification
or prognostication of patients with myeloproliferative diseases
should be addressed in future studies including a large number of
patients.
In conclusion, varying mechanisms (translocations, allelic
loss, insertions, promoter methylation and probably chromatin
modification) leading to an inactivation of GRAF can be observed
in a subset of AML and MDS cases. The pathogenetic role of
Table 2 Results of the MS-PCR
Sample Diagnosis, subtype MS-PCR result
1A M L , M 7  
2 AML, not classified +
3A M L , M 5 +
4A M L , M 5 +
5A M L , M 5 +
6 AML, not classified +
7A M L , M 5  
8A M L , M 4  
9A M L , M 4  
10 AML, M2  
11 AML, M2  
12 AML, M2  
13 AML, M2  
14 AML, M2  
15 AML, M2 +
16 MDS, JMML +
17 MDS, RAEB-T, ANLL +
18 MDS, RA  
19 MDS, RA  
20 MDS, CMML  
21 MDS, CMML +
22 MDS, not classified  
23 MDS, CMML +
24 MDS, not classified +
25 MDS, RAEB  
26 MDS, RA  
27 MDS, RA  
28 MDS, RAEB  
29 MDS, not classified  
MS-PCR¼methylation-sensitive PCR; AML¼acute myeloid leukaemia; MDS¼mye-
lodysplastic syndrome.
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established.
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